<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378378</url>
  </required_header>
  <id_info>
    <org_study_id>P04292</org_study_id>
    <nct_id>NCT00378378</nct_id>
  </id_info>
  <brief_title>Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)</brief_title>
  <official_title>Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Nasonex® (Mometasone
      Furoate Nasal Spray(MFNS)) in the treatment of nasal polyps in pediatric subjects between the
      ages of 6 and less than 18 years old. Safety will be the primary focus of this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline 24-hour Urinary Free Cortisol Level</measure>
    <time_frame>Baseline to Endpoint</time_frame>
    <description>The primary objective of this study was to evaluate the safety of Mometasone Furoate Nasal Spray (MFNS) in the treatment of pediatric subjects 6 to &lt;18 years of age. Primary safety was to be assessed by determining the subject's 24-hour urinary free cortisol level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline 24-hour Urinary Free Cortisol Level Corrected for Creatinine</measure>
    <time_frame>Baseline to Endpoint</time_frame>
    <description>The key secondary objective of this study was the assessment of the 24-hour urinary free cortisol level (corrected for creatinine).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>MFNS 100 mcg QD for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MFNS 200 mcg QD for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MFNS 200 mcg BID for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MFNS 100 mcg BID for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate Nasal Spray (MFNS)</intervention_name>
    <description>100 mcg nasal spray</description>
    <arm_group_label>MFNS 100 mcg QD for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_label>MFNS 200 mcg QD for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_label>MFNS 200 mcg BID for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_label>MFNS 100 mcg BID for subjects 6 to less than 12 years</arm_group_label>
    <other_name>Nasonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <description>One spray of placebo nasal spray in each nostril once daily for 4 months.</description>
    <arm_group_label>Placebo QD for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_label>Placebo QD for subjects 12 to less than 18 years</arm_group_label>
    <arm_group_label>Placebo BID for subjects 6 to less than 12 years</arm_group_label>
    <arm_group_label>Placebo BID for subjects 12 to less than 18 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject must be 6 to &lt;18 years of age, of either sex, and of any race.

          -  A subject must have a diagnosis of bilateral nasal polyps.

          -  A subject must have a minimum nasal congestion/obstruction

          -  An asthmatic subject may be included.

          -  A subject's clinical laboratory tests (hematology, blood chemistry, and urinalysis)
             must be within normal limits or clinically acceptable to the investigator/sponsor.

          -  The subject and parent/guardian must be willing to give written informed consent, and
             the subject must be able to adhere to dose and visit schedules.

          -  A female subject of child-bearing potential who is sexually active must have been
             using a medically accepted method of contraception prior to Screening and must
             continue using it while receiving protocol-specified medication. If a pre-menarche
             female subject begins menstruating during the study, a serum pregnancy test must be
             done at the next visit

        Exclusion Criteria:

          -  A subject with antrochoanal polyps.

          -  A subject with cystic fibrosis.

          -  A subject with acute sinusitis, concurrent upper respiratory tract infection, or who
             had an upper respiratory tract infection within 2 weeks prior to the Screening Visit.

          -  A subject with any clinically significant condition or situation, other than the
             condition being studied that, in the opinion of the investigator, would interfere with
             the study evaluations or optimal participation in the study.

          -  A subject who is immunocompromised.

          -  A subject with ongoing rhinitis medicamentosa.

          -  A subject with Churg Strauss syndrome.

          -  A subject with dyskinetic ciliary syndromes, eg, Young's syndrome (sinopulmonary
             infections and obstructive azoospermia) or Kartagener's syndrome (immotile cilia).

          -  A subject with any clinically significant pretreatment laboratory, vital sign, or ECG
             abnormality.

          -  A subject with allergy/sensitivity to aspirin, corticosteroids, or study drug or its
             excipients.

          -  A subject who has not observed the medication washout times outlined in the protocol
             prior to the Screening Visit.

          -  A female subject who is breast-feeding, pregnant, or intends to become pregnant.

          -  A subject who has used any investigational drug within 30 days of Screening.

          -  A subject who is part of the staff personnel directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Colombia</country>
    <country>El Salvador</country>
    <country>Guatemala</country>
    <country>Honduras</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Chur V, Small CB, Stryszak P, Teper A. Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children. Pediatr Allergy Immunol. 2013 Feb;24(1):33-8. doi: 10.1111/pai.12032.</citation>
    <PMID>23331528</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2006</study_first_posted>
  <results_first_submitted>June 24, 2009</results_first_submitted>
  <results_first_submitted_qc>June 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2010</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MFNS 100 or 200 mcg BID for Subjects 6 to Less Than 18 Years</title>
          <description>Subjects 6 to less than 12 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) twice per day (BID)</description>
        </group>
        <group group_id="P2">
          <title>MFNS 100 or 200 mcg QD for Subjects 6 to Less Than 18 Years</title>
          <description>Subject 12 to less than 18 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) once per day (QD)</description>
        </group>
        <group group_id="P3">
          <title>Pooled Placebo</title>
          <description>All placebo groups were combined</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MFNS 100 or 200 mcg BID for Subjects 6 to Less Than 18 Years</title>
          <description>Subjects 6 to less than 12 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) twice per day (BID)</description>
        </group>
        <group group_id="B2">
          <title>MFNS 100 or 200 mcg QD for Subjects 6 to Less Than 18 Years</title>
          <description>Subject 12 to less than 18 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) once per day (QD)</description>
        </group>
        <group group_id="B3">
          <title>Pooled Placebo</title>
          <description>All placebo groups were combined</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="1.4"/>
                    <measurement group_id="B2" value="14.4" spread="1.8"/>
                    <measurement group_id="B3" value="12.7" spread="3.2"/>
                    <measurement group_id="B4" value="12.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 to &lt; 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to &lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline 24-hour Urinary Free Cortisol Level</title>
        <description>The primary objective of this study was to evaluate the safety of Mometasone Furoate Nasal Spray (MFNS) in the treatment of pediatric subjects 6 to &lt;18 years of age. Primary safety was to be assessed by determining the subject’s 24-hour urinary free cortisol level.</description>
        <time_frame>Baseline to Endpoint</time_frame>
        <population>Not all participants that were randomized had both a baseline and an endpoint urine sample. Only participants with both were included in the participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>MFNS 100 or 200 mcg BID for Subjects 6 to Less Than 18 Years</title>
            <description>Subjects 6 to less than 12 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) twice per day (BID)</description>
          </group>
          <group group_id="O2">
            <title>MFNS 100 or 200 mcg QD for Subjects 6 to Less Than 18 Years</title>
            <description>Subject 12 to less than 18 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) once per day (QD)</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>All placebo groups were combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline 24-hour Urinary Free Cortisol Level</title>
          <description>The primary objective of this study was to evaluate the safety of Mometasone Furoate Nasal Spray (MFNS) in the treatment of pediatric subjects 6 to &lt;18 years of age. Primary safety was to be assessed by determining the subject’s 24-hour urinary free cortisol level.</description>
          <population>Not all participants that were randomized had both a baseline and an endpoint urine sample. Only participants with both were included in the participants analyzed.</population>
          <units>mcg/hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" spread="32.4"/>
                    <measurement group_id="O2" value="39.6" spread="32.4"/>
                    <measurement group_id="O3" value="49.8" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="42.9"/>
                    <measurement group_id="O2" value="11.6" spread="42.9"/>
                    <measurement group_id="O3" value="-2.1" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison p-values were based on a two-way ANOVA for the change from basline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.258</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison p-values were based on a two-way ANOVA for the change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.735</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison p-values were based on a two-way ANOVA for the change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline 24-hour Urinary Free Cortisol Level Corrected for Creatinine</title>
        <description>The key secondary objective of this study was the assessment of the 24-hour urinary free cortisol level (corrected for creatinine).</description>
        <time_frame>Baseline to Endpoint</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MFNS 100 or 200 mcg BID for Subjects 6 to Less Than 18 Years</title>
            <description>Subjects 6 to less than 12 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) twice per day (BID)</description>
          </group>
          <group group_id="O2">
            <title>MFNS 100 or 200 mcg QD for Subjects 6 to Less Than 18 Years</title>
            <description>Subject 12 to less than 18 years of age were pooled for Mometasone Furoate Nasal Spray (MFNS) once per day (QD)</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>All placebo groups were combined</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline 24-hour Urinary Free Cortisol Level Corrected for Creatinine</title>
          <description>The key secondary objective of this study was the assessment of the 24-hour urinary free cortisol level (corrected for creatinine).</description>
          <units>mcg/hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="4.5"/>
                    <measurement group_id="O2" value="5.3" spread="4.5"/>
                    <measurement group_id="O3" value="7.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="4.9"/>
                    <measurement group_id="O2" value="1.0" spread="4.9"/>
                    <measurement group_id="O3" value="-0.6" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison p-values were based on a two-way ANOVA for baseline to endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison p-values were based on a two-way ANOVA for baseline to endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison p-values were based on a two-way ANOVA for baseline to endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.193</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MFNS 100 or 200 mcg QD</title>
        </group>
        <group group_id="E2">
          <title>MFNS 100 or 200 mcg BID</title>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="32" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="32" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>NASAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The standard deviation is pooled for Primary and Secondary Outcome Measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice Presiden, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

